Archive: April, 2015

 

 

Rex Bionics plc and Deltason establish partnership to commercialise the REX Robot in Hong Kong

Rex Bionics plc, the pioneer of the REX Robot technology that enhances the mobility of wheelchair users and Deltason Medical Ltd, a distributor of rehabilitation equipment in Hong Kong and China, are pleased to announce that they have signed a distribution agreement in which Deltason will exclusively represent REX in Hong Kong, both in neuro-rehabilitation clinics and in the personal use market.

Read more about Rex Bionics plc and Deltason establish partnership to commercialise the REX Robot in Hong Kong

Avita Medical Granted CE Mark for Expanded ReCell™

Australia, 27 April 2015.

Read more about Avita Medical Granted CE Mark for Expanded ReCell™

Avita Medical Hosts International Skin Regeneration Symposium Attended by Leading Clinicians

Australia, 23 April 2015.

Read more about Avita Medical Hosts International Skin Regeneration Symposium Attended by Leading Clinicians

Avita Medical – Chronic wound RCT scoops Innovation Prize at Skin Regeneration Symposium

Cambridge, 21st April 2015 —Published results from a randomized control clinical trial that used Avita Medical’s skin regenerating device to successfully treat chronic wounds have won the lead clinician the ‘Avita Medical...

Read more about Avita Medical – Chronic wound RCT scoops Innovation Prize at Skin Regeneration Symposium

Avita Medical Appoints Adam Kelliher as Chief Executive Officer

Avita Medical Ltd.  (ASX: AVH ), (OTCQX: AVMXY), a regenerative medicine  company specializing in the treatment of wounds and skin defects, today announced the appointment  of  Mr. Adam Kelliher as Chief Executive Officer.

Read more about Avita Medical Appoints Adam Kelliher as Chief Executive Officer

AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

AmpliPhi BioSciences Corporation. (OTCQB: APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, “Bacteriophage-containing Therapeutic Agents”.

Read more about AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

SeaDragon Investor Update April 2015

SeaDragon (NZX:SEA) is New Zealand’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils. Our oils are sourced from fish caught in the clean and pure waters around New Zealand, in the Southern Ocean, and elsewhere.

Read more about SeaDragon Investor Update April 2015

Nexvet Biopharma Appoints Dr. George Gunn as Chairman

Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced it has appointed former Division Head of Novartis Animal Health Dr. George Gunn as non-executive chairman of the Nexvet Board of Directors. The appointment is effective from 31 March 2015.

Read more about Nexvet Biopharma Appoints Dr. George Gunn as Chairman